Default company panoramic image
751955e8 b4f4 4562 bcfe 9a0bc99f2ffd

Akrotome Imaging, Inc.

Our technology supports visualization of malignant tumors inter-operatively, targeting unmet medical needs in the $2B guided-surgery market.

  • Stage Product In Development
  • Industry Medical Devices and Equipment
  • Location Cleveland, OH, USA
  • Currency USD

Company Summary

Akrotome focuses on the translation of core research into new approaches to clinical practice and standards of care, reducing costs, enhancing quality of life for patients, and improving outcomes. Our patented molecular probes bind to proteases produced by cancers, making them glow brightly in near-infrared light. Our first product reduces repeat lumpectomy surgeries by 90%. We target clinicians and financial managers in top cancer centers.


  • Default avatar
    Brian Straight

    Brian Straight, Ph.D., has founded and managed successful life sciences companies. A former entrepreneur -in-residence at the Eli Lilly eLilly division, he has experience in developing technologies for FDA regulated environments, including informatics solutions for pharma, instrument companies, and CROs, as well as in the design and development of technologies for pathogen detection focused on the clinical and food safety markets.

  • Default avatar
    James Basilion
    Co-Founder/SAB Member

    James P. Basilion, Ph.D., Associate Professor, Case Western Reserve University, Departments of Radiology, Biomedical Engineering, and Pathology. Dr. Basilion's work is focused on molecular imaging and on its use in non-invasive imaging of cancer and other diseases. Dr. Basilion is co-director of the Cancer Imaging Program for the Case Comprehensive Cancer Center and he directs the NFCR Center for Molecular Imaging.

  • Default avatar
    Matthew Bogyo
    Co-Founder/SAB Member

    Dr. Bogyo is Associate Professor, Stanford University Departments of Pathology and Microbiology & Immunology. His group studies protease function in mouse models of cancer and human malaria and he has developed a number of valuable new reagents for applications from autoimmune disease to cancer and inflammation imaging. He also lead a group at Celera Genomics for two years, focused on the drug discovery area.


  • Default avatar
    Thorp Reed & Armstrong, LLP. Pittsburgh, PA
    Default avatar
    JLP CPA’s. Mentor, OH